Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer
M Gornitsky, G Shenouda, K Sultanem, H Katz… - Oral Surgery, Oral …, 2004 - Elsevier
OBJECTIVE: The efficacy of pilocarpine given during radiotherapy for head-neck cancer to
reduce xerostomia was assessed. STUDY DESIGN: 58 patients receiving 5000 cGy
radiotherapy (RT) involving salivary glands bilaterally were selected at the Jewish General
Hospital, Montreal, Canada. Patients were randomly assigned to pilocarpine (5 mg, PILO, n=
29) or placebo group (PLA, n= 29). These drugs were taken 5 times daily during
radiotherapy (first study phase) and 4 times daily for 5 weeks thereafter (second study …
reduce xerostomia was assessed. STUDY DESIGN: 58 patients receiving 5000 cGy
radiotherapy (RT) involving salivary glands bilaterally were selected at the Jewish General
Hospital, Montreal, Canada. Patients were randomly assigned to pilocarpine (5 mg, PILO, n=
29) or placebo group (PLA, n= 29). These drugs were taken 5 times daily during
radiotherapy (first study phase) and 4 times daily for 5 weeks thereafter (second study …
